logo-loader

CEL-SCI hopeful new data will show 10% improvement in cancer patients

Published: 10:07 20 Feb 2018 EST

CEO Geert Kersten from CEL-SCI (NYSE AMERICAN:CVM) tells Proactive Investors they are waiting for 298 events to show a 10 percent improvement in overall survival of how their investigational therapy can produce an anti-tumour response in a cancer patient's immune system. CEL-SCI is involved in cancer immunotherapy, boosting the immune system before radiation and chemotherapy. Kersten says he had invested half a million dollars into the company last year, and says they are positive that legal battles the company is facing will come to an end soon.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 17 minutes ago